Can ad hoc analyses of clinical trials help personalize treatment decisions?

被引：1
作者：
Biltaji, Eman [1 ,2 ,3 ]
Kumar, Shaun S. [1 ]
Enioutina, Elena Y. [1 ,4 ]
Sherwin, Catherine M. T. [1 ,2 ]
机构：
[1] Univ Utah, Sch Med, Div Clin Pharmacol, Dept Paediat, 30 N 1900 E, Salt Lake City, UT 84132 USA
[2] Univ Utah, Dept Pharmacotherapy, Coll Pharm, Salt Lake City, UT 84132 USA
[3] Univ Utah, Program Personalized Hlth, Salt Lake City, UT 84132 USA
[4] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2017年 / 83卷 / 11期
关键词：
PROGRESSIVE MULTIPLE-SCLEROSIS; COLORECTAL-CANCER; CETUXIMAB; PLACEBO;
D O I：
10.1111/bcp.13377
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：2337 / 2338
页数：2
相关论文
共 9 条
[1]   B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis [J].
Calabresi, Peter A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03) :280-282
[2]   Influence of Pharmacogenomic Profiling Prior to Pharmaceutical Treatment in Metastatic Colorectal Cancer on Cost Effectiveness A Systematic Review [J].
Frank, Martin ;
Mittendorf, Thomas .
PHARMACOECONOMICS, 2013, 31 (03) :215-228
[3]   Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial [J].
Hawker, Kathleen ;
O'Connor, Paul ;
Freedman, Mark S. ;
Calabresi, Peter A. ;
Antel, Jack ;
Simon, Jack ;
Hauser, Stephen ;
Waubant, Emmanuelle ;
Vollmer, Timothy ;
Panitch, Hillel ;
Zhang, Jiameng ;
Chin, Peter ;
Smith, Craig H. .
ANNALS OF NEUROLOGY, 2009, 66 (04) :460-471
[4]   Cetuximab for the treatment of colorectal cancer [J].
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Karapetis, Christos S. ;
Zalcberg, John R. ;
Tu, Dongsheng ;
Au, Heather-Jane ;
Berry, Scott R. ;
Krahn, Marianne ;
Price, Timothy ;
Simes, R. John ;
Tebbutt, Niall C. ;
van Hazel, Guy ;
Wierzbicki, Rafal ;
Langer, Christiane ;
Moore, Malcolm J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2040-2048
[5]   K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].
Karapetis, Christos S. ;
Khambata-Ford, Shirin ;
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Tu, Dongsheng ;
Tebbutt, Niall C. ;
Simes, R. John ;
Chalchal, Haji ;
Shapiro, Jeremy D. ;
Robitaille, Sonia ;
Price, Timothy J. ;
Shepherd, Lois ;
Au, Heather-Jane ;
Langer, Christiane ;
Moore, Malcolm J. ;
Zalcberg, John R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765
[6]   KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J].
Massarelli, Erminia ;
Varella-Garcia, Marileila ;
Tang, Ximing ;
Xavier, Ana C. ;
Ozburn, Natalie C. ;
Liu, Diane D. ;
Bekele, Benjamin N. ;
Herbst, Roy S. ;
Wistuba, Ignacio I. .
CLINICAL CANCER RESEARCH, 2007, 13 (10) :2890-2896
[7]   Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis [J].
Montalban, X. ;
Hauser, S. L. ;
Kappos, L. ;
Arnold, D. L. ;
Bar-Or, A. ;
Comi, G. ;
de Seze, J. ;
Giovannoni, G. ;
Hartung, H. -P. ;
Hemmer, B. ;
Lublin, F. ;
Rammohan, K. W. ;
Selmaj, K. ;
Traboulsee, A. ;
Sauter, A. ;
Masterman, D. ;
Fontoura, P. ;
Belachew, S. ;
Garren, H. ;
Mairon, N. ;
Chin, P. ;
Wolinsky, J. S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03) :209-220
[8]   KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib [J].
Pao, W ;
Wang, TY ;
Riely, GJ ;
Miller, VA ;
Pan, QL ;
Ladanyi, M ;
Zakowski, MF ;
Heelan, RT ;
Kris, MG ;
Varmus, HE .
PLOS MEDICINE, 2005, 2 (01) :57-61
[9]  
Weiss KD, 2004, APPROVAL LETT CETUXI
1